TY - JOUR
T1 - Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection
AU - Suzuki, Koichiro
AU - Shinzawa, Naoaki
AU - Ishigaki, Keisuke
AU - Nakamura, Keiji
AU - Abe, Hiroyuki
AU - Fukui-Miyazaki, Aya
AU - Ikuta, Kazuyoshi
AU - Horiguchi, Yasuhiko
N1 - Funding Information:
We would like to thank M. Kobayashi and H. Kanazi for their technical support, BIKEN Foundation for kindly providing B. pertussis strains and Y. Sato and H. Sato for their helpful discussions. This study was supported in part by JSPS KAKENHI funds to NS (26860286), KN (26860288), HA (26460525) and YH (26293096).
Publisher Copyright:
© 2017 The Societies and John Wiley & Sons Australia, Ltd
PY - 2017/9
Y1 - 2017/9
N2 - Bordetella pertussis causes whooping cough, a severe and prolonged respiratory disease that results inhas high morbidity and mortality rates, particularly in developing countries. The number incidence of whooping cough cases is increasing in many countries despite high vaccine coverage. Causes for the re-emergence of the disease include the limited duration of protection conferred by the acellular pertussis vaccines (aP)s and pathogenic adaptations that involve antigenic divergence from vaccine strains. Therefore, current vaccines therefore need to be improved. In the present study, we focused on five autotransporters: namely SphB1, BatB, SphB2, Phg, and Vag8, which were previously found to be expressed by B. bronchiseptica during the course of infection in rats and examined their protective efficiencies as vaccine antigens. The passenger domains of these proteins were produced in recombinant forms and used as antigens. An intranasal murine challenge assay showed that immunization with a mixture of SphB1 and Vag8 (SV) significantly reduced bacterial load in the lower respiratory tract and a combination of aP and SV acts synergistically in effects of conferring protection against B. pertussis infection, implying that these antigens have potential as components to for improvinge th the currently available acellular pertussis vaccine.
AB - Bordetella pertussis causes whooping cough, a severe and prolonged respiratory disease that results inhas high morbidity and mortality rates, particularly in developing countries. The number incidence of whooping cough cases is increasing in many countries despite high vaccine coverage. Causes for the re-emergence of the disease include the limited duration of protection conferred by the acellular pertussis vaccines (aP)s and pathogenic adaptations that involve antigenic divergence from vaccine strains. Therefore, current vaccines therefore need to be improved. In the present study, we focused on five autotransporters: namely SphB1, BatB, SphB2, Phg, and Vag8, which were previously found to be expressed by B. bronchiseptica during the course of infection in rats and examined their protective efficiencies as vaccine antigens. The passenger domains of these proteins were produced in recombinant forms and used as antigens. An intranasal murine challenge assay showed that immunization with a mixture of SphB1 and Vag8 (SV) significantly reduced bacterial load in the lower respiratory tract and a combination of aP and SV acts synergistically in effects of conferring protection against B. pertussis infection, implying that these antigens have potential as components to for improvinge th the currently available acellular pertussis vaccine.
UR - http://www.scopus.com/inward/record.url?scp=85029657366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029657366&partnerID=8YFLogxK
U2 - 10.1111/1348-0421.12504
DO - 10.1111/1348-0421.12504
M3 - Article
C2 - 28752940
AN - SCOPUS:85029657366
SN - 0385-5600
VL - 61
SP - 371
EP - 379
JO - MICROBIOLOGY and IMMUNOLOGY
JF - MICROBIOLOGY and IMMUNOLOGY
IS - 9
ER -